Should You Buy Merck After This Selloff?

There's no question that Merck is cheap

Brenton Flynn
Brenton Flynn
Feb 4, 2013 at 6:30PM
Health Care

Shares of blue-chip pharmaceutical company Merck (NYSE:MRK) have been clobbered (in big pharma terms) since reporting earnings on Friday. With the stock down more than 5% since that report, some investors might be looking to take action.

In the video below, health care bureau chief Brenton Flynn offers his opinion of Merck today, and whether investors should take the money and run -- or back up the truck and buy more.